Merck and Daiichi Sankyo's HER3 antibody-drug conjugate reported a positive phase 3 result in EGFR-mutated lung cancer. Merck ...

Positive opinion granted for KEYTRUDA plus chemotherapy for the first-line treatment of adult patients with primary advanced or recurrent endometrial carcinoma who are candidates for systemic therapy, ...

Development methodologies combine old and new techniques, but getting any new material into high-volume manufacturing is a ...

As the 10th anniversary of the Make in India initiative nears, CNBC’s Inside India takes a look at how the nation’s ...

MRK and Daiichi Sankyo's patritumab deruxtecan shows statistically significant progression-free survival improvement in ...

And then for GARDASIL, that again, one is the doubling of the volume. So where we were in 2019, there was some capacity constraints on our manufacturing supply. The team under the direction of Sanat ...

The firms will share data from the HERTHENA-Lung02 trial, in which patritumab deruxtecan improved patients' progression-free survival versus chemo.

Despite meeting the primary endpoint in a Phase III study, two patients treated with Merck and Daiichi Sankyo’s experimental ...

Under a MOU signed between both the parties, Merck and Siemens have decided to expand their cooperation in Smartfacturing.

The FDA previously rejected patritumab deruxtecan over manufacturing issues. Tuesday's study data should boost the companies' ...

A phase 3 trial of Daiichi Sankyo and Merck & Co.’s HER3-directed antibody-drug conjugate (ADC) has hit its primary endpoint, ...

The global cell therapy manufacturing market is poised for remarkable growth, with market size expected to reach USD 15,634.67 million by 2033, according to recent market projections. In 2023, the ...